Nanoparticles as contrast agents for the diagnosis of Alzheimer’s disease: a systematic review

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. World Alzheimer Report 2018. The state of the art of dementia research: new frontiers (2019). www.alz.co.uk/research/WorldAlzheimerReport2018.pdf
  Google Scholar
• 2. Jack CR Jr , Holtzman DM . Biomarker modeling of Alzheimer’s disease. Neuron 80(6), 1347–1358 (2013).
  Medline CASGoogle Scholar
• 3. Fagan AM , Xiong C , Jasielec MS et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci. Transl. Med. 6(226), 226ra230 (2014).
  Google Scholar
• 4. Carpenter BD , Xiong C , Porensky EK et al. Reaction to a dementia diagnosis in individuals with Alzheimer’s disease and mild cognitive impairment. J. Am. Geriatr. Soc. 56(3), 405–412 (2008).
  MedlineGoogle Scholar
• 5. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement. 14(3), 367–429 (2018).
  Google Scholar
• 6. Patterson C . World Alzheimer Report 2018: The State of the Art of Dementia Research: New Frontiers. Alzheimer’s Disease International, London, UK (2018).
  Google Scholar
• 7. Jack CR Jr , Bennett DA , Blennow K et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14(4), 535–562 (2018).
  MedlineGoogle Scholar
• 8. Molinuevo JL , Blennow K , Dubois B et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 10(6), 808–817 (2014).
  MedlineGoogle Scholar
• 9. Frisoni GB , Fox NC , Jack CR Jr , Scheltens P , Thompson PM . The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6(2), 67–77 (2010).
  MedlineGoogle Scholar
• 10. Yang L , Rieves D , Ganley C . Brain amyloid imaging – FDA approval of florbetapir F18 injection. N. Engl. J. Med. 367(10), 885–887 (2012).
  Medline CASGoogle Scholar
• 11. Sabri O , Sabbagh MN , Seibyl J et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase III study. Alzheimers Dement. 11(8), 964–974 (2015).
  MedlineGoogle Scholar
• 12. Fantoni ER , Chalkidou A , O’Brien JT , Farrar G , Hammers A . A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s disease. J. Alzheimers Dis. 63(2), 783–796 (2018).
  MedlineGoogle Scholar
• 13. Xia C-F , Arteaga J , Chen G et al. [¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 9(6), 666–676 (2013).
  MedlineGoogle Scholar
• 14. Wooten DW , Guehl NJ , Verwer EE et al. Pharmacokinetic evaluation of the tau PET radiotracer (¹⁸)F-T807 ((¹⁸)F-AV-1451) in human subjects. J. Nucl. Med. 58(3), 484–491 (2017).
  Medline CASGoogle Scholar
• 15. Lohith TG , Bennacef I , Vandenberghe R et al. Brain imaging of Alzheimer dementia patients and elderly controls with (¹⁸)F-MK-6240, a PET tracer targeting neurofibrillary tangles. J. Nucl. Med. 60(1), 107–114 (2019).
  Medline CASGoogle Scholar
• 16. Saint-Aubert L , Lemoine L , Chiotis K , Leuzy A , Rodriguez-Vieitez E , Nordberg A . Tau PET imaging: present and future directions. Mol. Neurodegener. 12(1), 19 (2017).
  MedlineGoogle Scholar
• 17. Betthauser TJ , Ellison PA , Murali D et al. Characterization of the radiosynthesis and purification of [(¹⁸)F]THK-5351, a PET ligand for neurofibrillary tau. Appl. Radiat. Isot. 130, 230–237 (2017).
  Medline CASGoogle Scholar
• 18. Johnson KA , Minoshima S , Bohnen NI et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J. Nucl. Med. 54(3), 476–490 (2013).
  Medline CASGoogle Scholar
• 19. Benveniste H , Einstein G , Kim KR , Hulette C , Johnson GA . Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy. Proc. Natl Acad. Sci. USA 96(24), 14079–14084 (1999).
  Medline CASGoogle Scholar
• 20. Jack CR Jr , Garwood M , Wengenack TM et al. In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent . Magn. Reson. Med. 52(6), 1263–1271 (2004).
  MedlineGoogle Scholar
• 21. Vanhoutte G , Dewachter I , Borghgraef P , Van Leuven F , Van der Linden A . Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magn. Reson. Med. 53(3), 607–613 (2005).
  Medline CASGoogle Scholar
• 22. Nakada T , Matsuzawa H , Igarashi H , Fujii Y , Kwee IL . In vivo visualization of senile-plaque-like pathology in Alzheimer’s disease patients by MR microscopy on a 7T system . J. Neuroimag. 18(2), 125–129 (2008).
  MedlineGoogle Scholar
• 23. Sigurdsson EM , Wadghiri YZ , Mosconi L et al. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 29(6), 836–847 (2008).
  Medline CASGoogle Scholar
• 24. Wadghiri YZ , Hoang DM , Wisniewski T , Sigurdsson EM . In vivo magnetic resonance imaging of amyloid-beta plaques in mice . Methods Mol. Biol. 849, 435–451 (2012).
  Medline CASGoogle Scholar
• 25. Chen Y , Lim P , Rogers KA , Rutt BK , Ronald JA . In vivo MRI of amyloid plaques in a cholesterol-fed rabbit model of Alzheimer’s disease . J. Alzheimers Dis. 64(3), 911–923 (2018).
  Medline CASGoogle Scholar
• 26. Monti S , Borrelli P , Tedeschi E , Cocozza S , Palma G . RESUME: turning an SWI acquisition into a fast qMRI protocol. PLoS ONE 12(12), e0189933 (2017).
  MedlineGoogle Scholar
• 27. Gong NJ , Dibb R , Bulk M , van der Weerd L , Liu C . Imaging beta amyloid aggregation and iron accumulation in Alzheimer’s disease using quantitative susceptibility mapping MRI. Neuroimage 191, 176–185 (2019).
  Medline CASGoogle Scholar
• 28. Park SM , Aalipour A , Vermesh O , Yu JH , Gambhir SS . Towards clinically translatable in vivo nanodiagnostics. Nat. Rev. Mater. 2(5), pii: 17014 (2017).
  Google Scholar
• 29. Ajetunmobi A , Prina-Mello A , Volkov Y , Corvin A , Tropea D . Nanotechnologies for the study of the central nervous system. Prog. Neurobiol. 123, 18–36 (2014).
  Medline CASGoogle Scholar
• 30. Huang J , Zhong X , Wang L , Yang L , Mao H . Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2(1), 86–102 (2012).
  MedlineGoogle Scholar
• 31. Plascencia-Villa G , Ponce A , Collingwood JF et al. High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer’s disease. Sci. Rep. 6, 24873 (2016).
  Medline CASGoogle Scholar
• 32. Tanifum EA , Ghaghada K , Vollert C , Head E , Eriksen JL , Annapragada A . A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging. J. Alzheimers Dis. 52(2), 731–745 (2016).
  Medline CASGoogle Scholar
• 33. Cheng KK , Chan PS , Fan S et al. Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials 44, 155–172 (2015). • Low cytotoxicity (up to 167 mg/ml) of cur-magnetic nanoparticles, considerable blood–brain barrier penetration and many hypointensities in MRI of Tg2576 brain in vivo.
  Medline CASGoogle Scholar
• 34. Sillerud LO , Solberg NO , Chamberlain R et al. SPION-enhanced magnetic resonance imaging of Alzheimer’s disease plaques in AbetaPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 34(2), 349–365 (2013).
  Medline CASGoogle Scholar
• 35. Li SS , Lin CW , Wei KC et al. Non-invasive screening for early Alzheimer’s disease diagnosis by a sensitively immunomagnetic biosensor. Sci. Rep. 6, 25155 (2016).
  Medline CASGoogle Scholar
• 36. Demeritte T , Nellore BP , Kanchanapally R et al. Hybrid graphene oxide based plasmonic-magnetic multifunctional nanoplatform for selective separation and label-free identification of Alzheimer’s disease biomarkers. ACS Appl. Mater. Interfaces 7(24), 13693–13700 (2015).
  Medline CASGoogle Scholar
• 37. Neely A , Perry C , Varisli B et al. Ultrasensitive and highly selective detection of Alzheimer’s disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nano 3(9), 2834–2840 (2009).
  Medline CASGoogle Scholar
• 38. Kouyoumdjian H , Zhu DC , El-Dakdouki MH et al. Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem. Neurosci. 4(4), 575–584 (2013).
  Medline CASGoogle Scholar
• 39. Moher D , Liberati A , Tetzlaff J , Altman DG . PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), e1000097 (2009).
  MedlineGoogle Scholar
• 40. Fernández T , Martínez-Serrano A , Cussó L , Desco M , Ramos-Gómez M . Functionalization and characterization of magnetic nanoparticles for the detection of ferritin accumulation in Alzheimer’s disease. ACS Chem. Neurosci. 9(5), 912–924 (2018).
  Medline CASGoogle Scholar
• 41. Zhou J , Fa H , Yin W et al. Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer’s disease. Mater. Sci. Eng. C Mater. Biol. Appl. 37, 348–355 (2014).
  Medline CASGoogle Scholar
• 42. Wadghiri YZ , Sigurdsson EM , Sadowski M et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50(2), 293–302 (2003).
  Medline CASGoogle Scholar
• 43. Yang J , Wadghiri YZ , Hoang DM et al. Detection of amyloid plaques targeted by USPIO-Abeta1-42 in Alzheimer’s disease transgenic mice using magnetic resonance microimaging. Neuroimage 55(4), 1600–1609 (2011).
  MedlineGoogle Scholar
• 44. Hu B , Dai F , Fan Z , Ma G , Tang Q , Zhang X . Nanotheranostics: congo Red/Rutin‐MNPs with enhanced magnetic resonance imaging and H₂O₂‐responsive therapy of Alzheimer’s disease in APPswe/PS1dE9 transgenic mice. Adv. Mater. 27(37), 5499–5505 (2015).
  Medline CASGoogle Scholar
• 45. Nasr Seyedmehdi H , Kouyoumdjian H , Mallett C et al. Detection of β‐amyloid by sialic acid coated bovine serum albumin magnetic nanoparticles in a mouse model of Alzheimer’s disease. Small 14(3), 1701828 (2017).
  Google Scholar
• 46. Wei Y , Quan L , Zhou C , Zhan Q . Factors relating to the biodistribution & clearance of nanoparticles & their effects on in vivo application. Nanomedicine (Lond.) 13(12), 1495–1512 (2018).
  CASGoogle Scholar
• 47. Solberg NO , Chamberlin R , Vigil JR et al. Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-κB concomitantly lower Alzheimer’s disease plaque formation and microglial activation in AβPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 40(1), 191–212 (2014).
  Medline CASGoogle Scholar
• 48. Tsolakis AC , Gounari E , Halevas E , Koliakos GG , Salifoglou A , Litsardakis G . Phagocytosis and cytotoxicity analysis of Thioflavin-T doped silica-coated superparamagnetic iron oxide nanoparticles bound to amyloid beta_1–42. IEEE Magn. Lett. 9, 1–5 (2018).
  Google Scholar
• 49. Zeng J , Wu J , Li M , Wang P . A novel magnetic nanoparticle for early detection of amyloid plaques in Alzheimer’s disease. Arch. Med. Res. 49(4), 282–285 (2018).
  Medline CASGoogle Scholar
• 50. Jaruszewski KM , Curran GL , Swaminathan SK et al. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer’s disease brain. Biomaterials 35(6), 1967–1976 (2014).
  Medline CASGoogle Scholar
• 51. Larbanoix L , Burtea C , Ansciaux E et al. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer’s disease: comparison with two cyclic heptapeptides derived from a randomized phage display library. Peptides 32(6), 1232–1243 (2011).
  Medline CASGoogle Scholar
• 52. Kim JH , Ha TL , Im GH et al. Magnetic resonance imaging for monitoring therapeutic response in a transgenic mouse model of Alzheimer’s disease using voxel-based analysis of amyloid plaques. Neuroreport 25(4), 211–218 (2014).
  Medline CASGoogle Scholar
• 53. Koffie RM , Farrar CT , Saidi LJ , William CM , Hyman BT , Spires-Jones TL . Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl Acad. Sci. USA 108(46), 18837–18842 (2011). • Exploitation of receptor-mediated transcytosis by adsorption of endogenous apoE onto nanoparticle surface.
  Medline CASGoogle Scholar
• 54. Ansciaux E , Burtea C , Laurent S et al. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood–brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging . Contrast Media Mol. Imaging 10(3), 211–224 (2015).
  Medline CASGoogle Scholar
• 55. Poduslo JF , Hultman KL , Curran GL et al. Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. J. Neuropathol. Exp. Neurol. 70(8), 653–661 (2011).
  Medline CASGoogle Scholar
• 56. Tafoya MA , Madi S , Sillerud LO . Superparamagnetic nanoparticle-enhanced MRI of Alzheimer’s disease plaques and activated microglia in 3X transgenic mouse brains: contrast optimization. J. Magn. Reson. Imaging 46(2), 574–588 (2017).
  MedlineGoogle Scholar
• 57. Mooradian AD , Chung HC , Shah GN . GLUT-1 expression in the cerebra of patients with Alzheimer’s disease. Neurobiol. Aging 18(5), 469–474 (1997).
  Medline CASGoogle Scholar
• 58. Sancey L , Kotb S , Truillet C et al. Long-term in vivo clearance of gadolinium-based AGuIX nanoparticles and their biocompatibility after systemic injection. ACS Nano 9(3), 2477–2488 (2015).
  Medline CASGoogle Scholar
• 59. Yin Z , Yu T , Xu Y . Preparation of amyloid immuno-nanoparticles as potential MRI contrast agents for Alzheimer’s disease diagnosis. J. Nanosci. Nanotechnol. 15(9), 6429–6434 (2015).
  Medline CASGoogle Scholar
• 60. Kim JH , Ha TL , Im GH et al. Magnetic resonance imaging of amyloid plaques using hollow manganese oxide nanoparticles conjugated with antibody aβ_1-40 in a transgenic mouse model. Neuroreport 24(1), 16–21 (2013).
  Medline CASGoogle Scholar
• 61. Yang CC , Yang SY , Chieh JJ et al. Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro . ACS Chem. Neurosci. 2(9), 500–505 (2011).
  Medline CASGoogle Scholar
• 62. Plissonneau M , Pansieri J , Heinrich-Balard L et al. Gd-nanoparticles functionalization with specific peptides for β-amyloid plaques targeting. J. Nanobiotechnol. 14(1), 60 (2016).
  MedlineGoogle Scholar
• 63. Sillerud LO , Solberg NO , Chamberlain R et al. SPION-enhanced magnetic resonance imaging of Alzheimer’s disease plaques in AbetaPP/PS-1 transgenic mouse brain. J. Alzheimers Dis. 34(2), 349–365 (2013).
  Medline CASGoogle Scholar
• 64. Andre S , Ansciaux E , Saidi E et al. Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid-beta and able to cross the blood–brain barrier. J. Alzheimers Dis. 60(4), 1547–1565 (2017).
  Medline CASGoogle Scholar
• 65. Ahlschwede KM , Curran GL , Rosenberg JT et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer’s disease brain. Nanomedicine 16, 258–266 (2018).
  MedlineGoogle Scholar
• 66. Agyare EK , Jaruszewski KM , Curran GL et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J. Control. Rel. 185, 121–129 (2014). •• Conjugation of gadolinium-based contrast agent Magnevist to a chitosan nanovehicle attenuated gadolinium toxicity and accumulation while retaining high-contrast enhancement.
  Medline CASGoogle Scholar
• 67. Li Y , Xu D , Chan HN et al. Dual-modal NIR-fluorophore conjugated magnetic nanoparticle for imaging amyloid-beta species in vivo . Small 14(28), e1800901 (2018).
  MedlineGoogle Scholar
• 68. Wadghiri YZ , Li J , Wang J et al. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer’s disease transgenic mice using magnetic resonance microimaging. PLoS ONE 8(2), e57097 (2013).
  Medline CASGoogle Scholar
• 69. Viola KL , Sbarboro J , Sureka R et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer’s disease. Nat. Nanotechnol. 10(1), 91–98 (2015).
  Medline CASGoogle Scholar
• 70. Plissonneau M , Pansieri J , Heinrich-Balard L et al. Gd-nanoparticles functionalization with specific peptides for s-amyloid plaques targeting. J. Nanobiotechnol. 14(1), 60 (2016).
  MedlineGoogle Scholar
• 71. Pansieri J , Plissonneau M , Stransky-Heilkron N et al. Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting. Nanomedicine (Lond.) 12(14), 1675–1687 (2017).
  CASGoogle Scholar
• 72. Pintaske J , Martirosian P , Graf H et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest. Radiol. 41(3), 213–221 (2006).
  MedlineGoogle Scholar
• 73. Skaat H , Corem-Slakmon E , Grinberg I et al. Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-beta fibrils. Int. J. Nanomedicine 8, 4063–4076 (2013).
  MedlineGoogle Scholar
• 74. Sancey L , Lux F , Kotb S et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Brit. J. Radiol. 87(1041), 20140134 (2014).
  Medline CASGoogle Scholar
• 75. Zhang D , Fa HB , Zhou JT , Li S , Diao XW , Yin W . The detection of beta-amyloid plaques in an Alzheimer’s disease rat model with DDNP-SPIO. Clin. Radiol. 70(1), 74–80 (2015).
  Medline CASGoogle Scholar
• 76. Ashburn TT , Han H , McGuinness BF , Lansbury PT Jr . Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem. Biol. 3(5), 351–358 (1996).
  Medline CASGoogle Scholar
• 77. Tanifum EA , Dasgupta I , Srivastava M et al. Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice. PLoS ONE 7(10), e48515 (2012).
  Medline CASGoogle Scholar
• 78. Patil R , Gangalum PR , Wagner S et al. Curcumin targeted, polymalic acid-based MRI contrast agent for the detection of abeta plaques in Alzheimer’s disease. Macromol. Biosci. 15(9), 1212–1217 (2015).
  Medline CASGoogle Scholar
• 79. Montagne A , Barnes SR , Sweeney MD et al. Blood–brain barrier breakdown in the aging human hippocampus. Neuron 85(2), 296–302 (2015).
  Medline CASGoogle Scholar
• 80. Sweeney MD , Sagare AP , Zlokovic BV . Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133 (2018).
  Medline CASGoogle Scholar
• 81. Dickstein DL , Biron KE , Ujiie M , Pfeifer CG , Jeffries AR , Jeffries WA . Aβ peptide immunization restores blood–brain barrier integrity in Alzheimer disease. FASEB J. 20(3), 426–433 (2006).
  Medline CASGoogle Scholar
• 82. Fryer JD , Taylor JW , Demattos RB et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci. 23(21), 7889 (2003).
  Medline CASGoogle Scholar
• 83. Poduslo JF , Curran GL , Wengenack TM , Malester B , Duff K . Permeability of proteins at the blood–brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8(4), 555–567 (2001).
  Medline CASGoogle Scholar
• 84. Van De Haar HJ , Burgmans S , Jansen JFA et al. Blood–brain barrier leakage in patients with early Alzheimer disease. Radiol. 281(2), 527–535 (2016).
  Google Scholar
• 85. Dickie BR , Vandesquille M , Ulloa J , Boutin H , Parkes LM , Parker GJM . Water-exchange MRI detects subtle blood–brain barrier breakdown in Alzheimer’s disease rats. Neuroimage 184, 349–358 (2019).
  MedlineGoogle Scholar
• 86. Horwood N , Davies DC . Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer’s disease. Virchows Arch. 425(1), 69–72 (1994).
  Medline CASGoogle Scholar
• 87. Hooijmans CR , Graven C , Dederen PJ , Tanila H , van Groen T , Kiliaan AJ . Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res. 1181, 93–103 (2007).
  Medline CASGoogle Scholar
• 88. Shigemoto-Mogami Y , Hoshikawa K , Sato K . Activated microglia disrupt the blood–brain barrier and induce chemokines and cytokines in a rat in vitro model. Front. Cell Neurosci. 12, 494 (2018).
  Medline CASGoogle Scholar
• 89. Frank S , Burbach GJ , Bonin M et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56(13), 1438–1447 (2008).
  MedlineGoogle Scholar
• 90. Lue LF , Schmitz CT , Serrano G , Sue LI , Beach TG , Walker DG . TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 25(4), 469–480 (2015).
  Medline CASGoogle Scholar
• 91. Wang Y , Cella M , Mallinson K et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160(6), 1061–1071 (2015).
  Medline CASGoogle Scholar
• 92. Patel MM , Patel BM . Crossing the blood–brain barrier: recent advances in drug delivery to the brain. CNS Drugs 31(2), 109–133 (2017).
  Medline CASGoogle Scholar
• 93. Songjiang Z , Lixiang W . Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech 10(3), 900 (2009).
  MedlineGoogle Scholar
• 94. Santin MD , Debeir T , Bridal SL , Rooney T , Dhenain M . Fast in vivo imaging of amyloid plaques using mu-MRI Gd-staining combined with ultrasound-induced blood–brain barrier opening. Neuroimage 79, 288–294 (2013).
  Medline CASGoogle Scholar
• 95. Hersh DS , Anastasiadis P , Mohammadabadi A et al. MR-guided transcranial focused ultrasound safely enhances interstitial dispersion of large polymeric nanoparticles in the living brain. PLoS ONE 13(2), e0192240 (2018).
  MedlineGoogle Scholar
• 96. Nance E , Timbie K , Miller GW et al. Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood–brain barrier using MRI-guided focused ultrasound. J. Control. Rel. 189, 123–132 (2014).
  Medline CASGoogle Scholar
• 97. Kang YS , Jung HJ , Oh JS , Song DY . Use of PEGylated immunoliposomes to deliver dopamine across the blood–brain barrier in a rat model of Parkinson’s disease. CNS Neurosci. Ther. 22(10), 817–823 (2016).
  Medline CASGoogle Scholar
• 98. Ansciaux E , Burtea C , Laurent S et al. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood–brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging . Contrast Media Mol. Imaging 10(3), 211–224 (2015).
  Medline CASGoogle Scholar
• 99. Skowronek M , Roterman I , Konieczny L et al. The conformational characteristics of Congo red, Evans blue and Trypan blue. Comput. Chem. 24(3–4), 429–450 (2000).
  Medline CASGoogle Scholar
• 100. Raymond SB , Treat LH , Dewey JD , McDannold NJ , Hynynen K , Backsai BJ . Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer’s disease mouse models. PLoS ONE 3(5), e2175 (2008).
  MedlineGoogle Scholar
• 101. Rajan RS , Li T , Aras M et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 15(5), 1063–1075 (2006).
  Medline CASGoogle Scholar
• 102. Suk JS , Xu Q , Kim N , Hanes J , Ensign LM . PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99(Pt A), 28–51 (2016).
  Medline CASGoogle Scholar
• 103. Pike CJ , Walencewicz AJ , Glabe CG , Cotman CW . Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207(4), 367–368 (1991).
  Medline CASGoogle Scholar
• 104. Zhang Y , McLaughlin R , Goodyer C , LeBlanc A . Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol. 156(3), 519–529 (2002).
  Medline CASGoogle Scholar
• 105. Grobner T , Prischl FC . Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin. Dialysis 21(2), 135–139 (2008).
  MedlineGoogle Scholar
• 106. Barbieri S , Schroeder C , Froehlich JM , Pasch A , Theony HC . High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. Contrast Media Mol. Imaging 11(3), 245–250 (2016).
  Medline CASGoogle Scholar
• 107. Gallez B , Bacic G , Swartz HM . Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn. Reson. Med. 35(1), 14–19 (1996).
  Medline CASGoogle Scholar
• 108. Crossgrove J , Zheng W . Manganese toxicity upon overexposure. NMR Biomed. 17(8), 544–553 (2004).
  Medline CASGoogle Scholar
• 109. Shin J , Anisur RM , Ko MK , Im GH , Lee JH , Lee IS . Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew. Chem. Int. 48(2), 321–324 (2009).
  Medline CASGoogle Scholar
• 110. An K , Kwon SG , Park M et al. Synthesis of uniform hollow oxide nanoparticles through nanoscale acid etching. Nano Lett. 8(12), 4252–4258 (2008).
  Medline CASGoogle Scholar
• 111. Ahmad A , Bae H , Rhee I . Highly stable silica-coated manganese ferrite nanoparticles as high-efficacy T₂ contrast agents for magnetic resonance imaging. AIP Adv. 8(5), 055019 (2018).
  Google Scholar
• 112. Mahmoudi M , Quinlan-Pluck F , Monopoli MP et al. Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution. ACS Chem. Neurosci. 4(3), 475–485 (2013).
  Medline CASGoogle Scholar
• 113. Frohlich E . The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 7, 5577–5591 (2012).
  MedlineGoogle Scholar
• 114. Lundqvist M , Stigler J , Elia G , Lynch I , Cedervall T , Dawson KA . Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265 (2008).
  Medline CASGoogle Scholar
• 115. Walkey CD , Olsen JB , Guo H , Emili A , Chan WCW . Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134(4), 2139–2147 (2012).
  Medline CASGoogle Scholar
• 116. Khandhar AP , Keselman P , Kemp SJ et al. Evaluation of PEG-coated iron oxide nanoparticles as blood pool tracers for preclinical magnetic particle imaging. Nanoscale 9(3), 1299–1306 (2017).
  Medline CASGoogle Scholar
• 117. Ferguson RM , Khandhar AP , Kemp SJ et al. Magnetic particle imaging with tailored iron oxide nanoparticle tracers. IEEE Trans. Med. Imaging 34(5), 1077–1084 (2015).
  MedlineGoogle Scholar
• 118. FDA clears first 7T magnetic resonance imaging device (2019). www.fda.gov/news-events/press-announcements/fda-clears-first-7t-magnetic-resonance-imaging-device
  Google Scholar
• 119. Lam T , Pouliot P , Avti PK , Lesage F , Kakkar AK . Superparamagnetic iron oxide based nanoprobes for imaging and theranostics. Adv. Colloid Interfac. 199–200, 95–113 (2013).
  Medline CASGoogle Scholar
• 120. McGrath AJ , Dolan C , Cheong S et al. Stability of polyelectrolyte-coated iron nanoparticles for T₂-weighted magnetic resonance imaging. J. Magn. Magn. Mater. 439, 251–258 (2017).
  CASGoogle Scholar
• 121. Tong S , Hou S , Zheng Z , Zhou J , Bao G . Coating optimization of superparamagnetic iron oxide nanoparticles for high T₂ relaxivity. Nano Lett. 10(11), 4607–4613 (2010).
  Medline CASGoogle Scholar
• 122. Liu Y , Wang Y , Zhou S et al. Synthesis of high saturation magnetization superparamagnetic Fe₃O₄ hollow microspheres for swift chromium removal. ACS Appl. Mater. Interfaces 4(9), 4913–4920 (2012).
  Medline CASGoogle Scholar
• 123. Maher BA , Ahmed IAM , Karloukovski V et al. Magnetite pollution nanoparticles in the human brain. Proc. Natl Acad. Sci. USA 113(39), 10797 (2016).
  Medline CASGoogle Scholar
• 124. McGrath AJ , Cheong S , Henning AM , Gooding JJ , Tilley RD . Size and shape evolution of highly magnetic iron nanoparticles from successive growth reactions. Chem. Commun. (Camb.) 53(84), 11548–11551 (2017).
  Medline CASGoogle Scholar
• 125. Cheong S , Ferguson P , Feindel KW et al. Simple synthesis and functionalization of iron nanoparticles for magnetic resonance imaging. Angew. Chem. 123(18), 4292–4295 (2011).
  Google Scholar
• 126. Faria M , Björnmalm M , Thurecht KJ et al. Minimum information reporting in bio–nano experimental literature. Nat. Nanotechnol. 13(9), 777–785 (2018). • Minimum information standard guidelines for bio-nanoresearch to improve reported research quality.
  Medline CASGoogle Scholar
• 127. Mahmoudi M , Laurent S , Shokrgozar MA , Hosseinkhani M . Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell “vision” versus physicochemical properties of nanoparticles. ACS Nano 5(9), 7263–7276 (2011).
  Medline CASGoogle Scholar
• 128. Toth GB , Varallyay CG , Horvath A et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 92(1), 47–66 (2017).
  Medline CASGoogle Scholar
• 129. Mundt AP , Winter C , Mueller S et al. Targeting activated microglia in Alzheimer’s pathology by intraventricular delivery of a phagocytosable MRI contrast agent in APP23 transgenic mice. Neuroimage 46(2), 367–372 (2009).
  MedlineGoogle Scholar
• 130. Fernandez-Cabada T , Ramos-Gomez M . A novel contrast agent based on magnetic nanoparticles for cholesterol detection as Alzheimer’s disease biomarker. Nanoscale Res. Lett. 14(1), 36 (2019).
  MedlineGoogle Scholar
• 131. Zhou XY , Tay ZW , Chandrasekharan P et al. Magnetic particle imaging for radiation-free, sensitive and high-contrast vascular imaging and cell tracking. Curr. Opin. Chem. Biol. 45, 131–138 (2018).
  Medline CASGoogle Scholar